[1] JIANG J, QIN F, MENG S, et al. Effects of cotrimoxazole prophylaxis on Talaromyces marneffei infection in HIV/AIDS patients receiving antiretroviral therapy: a retrospective cohort stud[J]. Emerg Microbes Infect,2019,8(1):367-376.
[2] 中华医学会热带病与寄生虫学分会艾滋病学组.艾滋病合并侵袭性真菌病诊治专家共识[J]. 中华临床感染病杂志, 2019, 12(4):253-267.
[3] LI Y, LUO H, FAN J, et al. Genomic analysis provides insights into the transmission and pathogenicity of Talaromyces marneffei[J]. Fungal Genet Biol,2019,130:54-61.DOI:10.1016/j.fgb.2019.05.002.
[4] 杨金玲,仇以利,王婉玲,等.粗针穿刺确诊马尔尼菲篮状菌感染性淋巴结炎的临床病理分析[J].中国医学科学院学报,2022,44(3):440-445.
[5] LI Y Y, DONG R J, SHRESTHA S, et al. AIDS-associated Talaromyces marneffei central nervous system infection in patients of southwestern China[J]. AIDS Res Ther,2020,17(1):26.
[6] GUO J, NING X Q, DING J Y, et al. Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections[J].J Exp Med,2020,217(12):e20190502.
[7] WEI W, NING C, HUANG J,et al. Talaromyces marneffei promotes M2-like polarization of human macrophages by downregulating SOCS3 expression and activating the TLR9 pathway[J]. Virulence, 2021,12(1):1997-2012.
[8] 黄晓云,陈玲.伏立康唑一级预防急性白血病患者化疗期间并发真菌感染的临床疗效[J].现代肿瘤医学,2022,30(21):3944-3947.
[9] ANDERSEN C U, SØNDERSKOV L D, BENDSTRUP E, et al. Voriconazole concentrations in plasma and epithelial lining fluid after inhalation and oral treatment[J]. Basic Clin Pharmacol Toxicol, 2017,121(5):430-434.
[10] 瞿青林,张静,鲁莎,等.不同交配型马尔尼菲篮状菌的抗真菌药物敏感性[J].菌物学报,2021,40(7):1881-1885.
[11] 蒋婷婷,翁翠莲,黄毅婷,等.伏立康唑潜在中毒浓度的危险因素研究[J].中国现代应用药学,2022,39(4):524-528.
[12] 张莎莎,李金纯,张雪丽,等.伏立康唑治疗新生儿侵袭性真菌感染的药学实践[J].中国药物应用与监测,2022,19(1):55-58.
[13] 黄小红,胡家光,莫胜林,等.两种方案治疗艾滋病合并马尔尼菲蓝状菌病的临床疗效对比研究[J].医学理论与实践,2021,34(2):193-195,183.
[14] 魏金瑛,欧阳沿音,蔡双启,等.伏立康唑治疗播散性马尔尼菲蓝状菌病临床分析[J].中国真菌学杂志,2017,12(2):92-97.
[15] 陈涛,兰慧慧,蒋忠胜,等.播散性马尔尼菲篮状菌病并发消化道出血患者近期预后的Cox回归生存分析[J].中国感染与化疗杂志,2022,22(5):538-544.
[16] 张馨予,潘开素,罗宏,等.中药小檗碱协同抗真菌药对马尔尼菲篮状菌的体外药敏试验研究[J].中国真菌学杂志,2021,16(3):176-181.
[17] HUANG W, LI T, ZHOU C, et al. Voriconazole versus amphotericin B as induction therapy for talaromycosis in HIV/AIDS patients: A retrospective study[J]. Mycopathologia, 2021,186(2):269-276.
[18] MAERTENS J A, RAHAV G, LEE D G, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial[J]. Lancet,2021,397(10273):499-509.
[19] 张春燕,钟蕾,黄琳,等.北京地区近10年伏立康唑致严重不良反应分析[J].中国新药杂志,2022,31(16):1645-1649.
[20] 柴双,展敬伦,肇丽梅,等.5种三唑类抗真菌药物的药物不良反应分析[J].中国临床药理学杂志,2022,38(17):2079-2083.
[21] 柳熠鑫,李珊,任菲菲,等.体外膜肺氧合对抗真菌药物药动学的影响[J].医药导报,2022,41(10):1480-1485.
[22] ALLEGRA S, FATIGUSO G, DE FRANCIA S, et al. Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children[J]. Br J Clin Pharmacol,2018,84(1):197-203.
[23] CHENG L, XIANG R, LIU F, et al. Therapeutic drug monitoring and safety of voriconazole in elderly patients[J]. Int Immunopharmacol,2020,78:106078. DOI: 10.1016/j.intimp.2019.106078.
[24] TANG D, YAN M, SONG B L, et al. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study[J]. Br J Clin Pharmacol,2021,87(4):1890-1902. |
